Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Ophthalmic vein

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    7 result(s) found for: Ophthalmic vein. Displaying page 1 of 1.
    EudraCT Number: 2004-002502-29 Sponsor Protocol Number: 206207-009 Start Date*: 2004-12-08
    Sponsor Name:Allergan Limited
    Full Title: A Six-Month Phase 3, Multicenter, Masked, Randomized, Sham-Controlled Trial (with Six-Month Open-Label Extension) to Assess the Safety and Efficacy of 700 µg and 350 µg Dexamethasone Posterior Segm...
    Medical condition: Macular edema due to Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2008-006265-93 Sponsor Protocol Number: AVO1 Start Date*: 2009-03-11
    Sponsor Name:St Eriks Eye Hospital
    Full Title: A prospective, randomized, masked and controlled trial of intravitreal bevacizumab (Avastin®) for central retinal vein occlusion (CRVO).
    Medical condition: Central retinal vein occlusion (CRVO) is a sight-threatening ocular condition without efficient treatment.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-000425-72 Sponsor Protocol Number: RET-01-11 Start Date*: 2011-01-25
    Sponsor Name:IRCCS- FONDAZIONE G.B. BIETTI PER LO STUDIO E LA RICERCA IN OFTALMOLOGIA-ONLUS
    Full Title: Treatment of macular edema secondary to central or branch vein occlusion by dexamethazone intravitreal injection
    Medical condition: macular edema seconday to central or branch retinal vein occlusion
    Disease: Version SOC Term Classification Code Term Level
    13.1 10015919 - Eye disorders 10015919 Eye disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-001061-37 Sponsor Protocol Number: KS301P103 Start Date*: 2020-12-11
    Sponsor Name:Kodiak Sciences Inc.
    Full Title: A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal A...
    Medical condition: Macular edema secondary to retinal vein occlusion
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10067791 Wet macular degeneration LLT
    20.0 10015919 - Eye disorders 10015919 Eye disorders SOC
    20.0 10015919 - Eye disorders 10054467 Macular edema LLT
    20.1 10015919 - Eye disorders 10057934 Diabetic macular edema LLT
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Prematurely Ended) DE (Completed) SK (Prematurely Ended) CZ (Prematurely Ended) FR (Prematurely Ended) HU (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-005486-13 Sponsor Protocol Number: 12-EI-0134 Start Date*: 2013-02-25
    Sponsor Name:The National Eye Institute
    Full Title: A Phase II Randomized Study to Compare Anti-VEGF Agents in the Treatment of Diabetic Macular Edema (CADME)
    Medical condition: Diabetic Macular Edema (DME)
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004853 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-005364-57 Sponsor Protocol Number: HLX04-O-wAMD Start Date*: 2021-04-06
    Sponsor Name:Shanghai Henlius Biotech. Inc.
    Full Title: A Phase 3, Two-part (Open-label Followed by Randomized Double-masked Active Controlled) Study to Compare the Efficacy and Safety of HLX04-O Administered by Intravitreal Injection with ranibizumab i...
    Medical condition: Wet Age-related Macular Degeneration (wAMD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10075568 Wet age-related macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) HU (Completed) CZ (Prohibited by CA) PL (Completed) ES (Ongoing) SK (Completed) BG (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000113-31 Sponsor Protocol Number: TED01RV Start Date*: 2014-07-14
    Sponsor Name:River Vision Development Corporation
    Full Title: A randomized, double-masked, placebo-controlled, efficacy and safety study of RV 001, an insulin-like growth factor-1 receptor (IGF-1R) antagonist antibody (fully human), administered every 3 weeks...
    Medical condition: Thyroid-Associated Ophthalmopathy / Graves' Ophthalmopathy
    Disease: Version SOC Term Classification Code Term Level
    18.1 10015919 - Eye disorders 10015919 Eye disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) GB (Completed) NL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jul 05 01:28:34 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA